Nwosu, Zeribe C. http://orcid.org/0000-0003-1641-2045
Ward, Matthew H.
Sajjakulnukit, Peter http://orcid.org/0000-0002-8556-7481
Poudel, Pawan
Ragulan, Chanthirika
Kasperek, Steven http://orcid.org/0000-0002-1895-2056
Radyk, Megan
Sutton, Damien
Menjivar, Rosa E.
Andren, Anthony
Apiz-Saab, Juan J.
Tolstyka, Zachary
Brown, Kristee
Lee, Ho-Joon http://orcid.org/0000-0003-3616-5387
Dzierozynski, Lindsey N.
He, Xi http://orcid.org/0000-0002-5802-2507
PS, Hari
Ugras, Julia http://orcid.org/0009-0003-8389-5478
Nyamundanda, Gift
Zhang, Li
Halbrook, Christopher J. http://orcid.org/0000-0002-3376-3114
Carpenter, Eileen S.
Shi, Jiaqi
Shriver, Leah P.
Patti, Gary J. http://orcid.org/0000-0002-3748-6193
Muir, Alexander
Pasca di Magliano, Marina
Sadanandam, Anguraj http://orcid.org/0000-0001-8485-5150
Lyssiotis, Costas A. http://orcid.org/0000-0001-9309-6141
Article History
Received: 21 June 2021
Accepted: 12 April 2023
First Online: 17 May 2023
Competing interests
: C.A.L. has received consulting fees from Astellas Pharmaceuticals, Odyssey Therapeutics, and T-Knife Therapeutics, and is an inventor on patents pertaining to KRAS-regulated metabolic pathways, redox control pathways in pancreatic cancer, and targeting the GOT1-pathway as a therapeutic approach (US patent 2015126580-A1, 05/07/2015; US patent 20190136238, 05/09/2019; international patent WO2013177426-A2, 04/23/2015). A.S. received grants from Merck, Pierre Fabre and Bristol Myers Squibb and is an inventor on patents on colorectal cancer classification with differential prognosis and personalized therapeutic responses (PCT/IB2013/060416); prognostic and treatment response prediction in gastric cancer (priority patent CSC/BP7295892); patient classification and prognostic method (GEP-NET) (priority patent EP18425009.0); and molecular predictors of therapeutic response to specific anti-cancer agents (US9506926B2).